NCT03895840View on ClinicalTrials.gov

The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 19, 2018

Primary Completion Date

May 3, 2021

Study Completion Date

May 3, 2021

Conditions
Knee Osteoarthritis
Interventions
DRUG

Zilretta

Zilretta (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee osteoarthritis.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

NCT03895840 - The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA | Biotech Hunter | Biotech Hunter